All In Biotech

Drug Trial Radar · NCT07216482

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 996 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

996

Actual

Start

Nov 11, 2025

Primary completion

Aug 3, 2026

Study completion Oct 27, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.

Conditions

  • Hyperlipidemia

Interventions

  • EnlicitideDrug

    Oral Tablet

  • RosuvastatinDrug

    Oral Capsule

  • Placebo for EnlicitideDrug

    Oral Tablet

  • Placebo for RosuvastatinDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change from Baseline in LDL-C at Week 8 (Enlicitide + Rosuvastatin Versus Placebo)Time frame: Baseline and Week 8

Locations

87 sites in 11 countries. Site status is shown where the registry gives one.

  • Central Research Associates ( Site 0009)

    Birmingham, Alabama

  • G&L Research ( Site 0024)

    Foley, Alabama

  • Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030)

    Phoenix, Arizona

  • Alliance for Multispecialty Research LLC ( Site 0049)

    Tempe, Arizona

  • Chemidox Clinical Trials ( Site 0008)

    Lancaster, California

  • Clinical Trials Research ( Site 0036)

    Sacramento, California

  • Legacy Clinical Trials ( Site 0044)

    Colorado Springs, Colorado

  • Alliance for Multispecialty Research, LLC ( Site 0040)

    Fort Myers, Florida

  • Soffer Health Institute ( Site 0046)

    Hollywood, Florida

  • East Coast Institute for Research ( Site 0041)

    Lake City, Florida

  • Inpatient Research Clinic ( Site 0017)

    Miami Lakes, Florida

  • Clinical Research Trials of Florida ( Site 0001)

    Tampa, Florida

  • Clinical Site Partners LLC, dba CSP Orlando ( Site 0014)

    Winter Park, Florida

  • Trialmed ( Site 0026)

    Chicago, Illinois

  • Great Lakes Clinical Trials - Ravenswood ( Site 0018)

    Chicago, Illinois

  • Midwest Institute For Clinical Research ( Site 0033)

    Indianapolis, Indiana

  • Alliance for Multispecialty Research, LLC ( Site 0048)

    Newton, Kansas

  • Cotton O'Neil Clinical Research Center ( Site 0006)

    Topeka, Kansas

  • L-MARC Research Center ( Site 0004)

    Louisville, Kentucky

  • Jubilee Clinical Research ( Site 0031)

    Las Vegas, Nevada

  • Cardiovascular Associates of the Delaware Valley ( Site 0035)

    Elmer, New Jersey

  • New Mexico Clinical Research & Osteoporosis Center, Inc. ( Site 0027)

    Albuquerque, New Mexico

  • Alliance for Multispecialty Research, LLC - Norman ( Site 0043)

    Norman, Oklahoma

  • Cardiology Consultants of Philadelphia Yardley ( Site 0016)

    Yardley, Pennsylvania

  • Provecta Research Network LLC ( Site 0022)

    Houston, Texas

  • Permian Research Foundation ( Site 0005)

    Odessa, Texas

  • LinQ Research ( Site 0025)

    Pearland, Texas

  • Clinical Trials of Texas, Inc. ( Site 0010)

    San Antonio, Texas

  • Stone Oak, LLC dba Discovery Clinical Trials (DCT) ( Site 0021)

    San Antonio, Texas

  • LinQ Research - Tomball ( Site 0047)

    Tomball, Texas

  • Conquest Research ( Site 0045)

    Arlington, Virginia

  • Manassas Clinical Research Center ( Site 0002)

    Manassas, Virginia

  • Health Research of Hampton Roads, Inc. ( Site 0013)

    Newport News, Virginia

  • National Clinical Research, Inc ( Site 0028)

    Richmond, Virginia

  • Rainier Clinical Research ( Site 0023)

    Renton, Washington

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0206)

    CABA, Argentina

  • Instituto de Cardiología "Juana F. Cabral"-Cardiología ( Site 0205)

    Corrientes, Argentina

  • CEMEDIC ( Site 0201)

    CABA, Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0202)

    Mar del Plata, Buenos Aires, Argentina

  • CIPREC-CIPREC Sede Arenales ( Site 0200)

    Buenos Aires, Buenos Aires F.D., Argentina

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.